Cohort plc (LON:CHRT – Get Free Report) insider Andrew Stephen Thomis bought 189 shares of the company’s stock in a transaction that occurred on Wednesday, October 15th. The shares were acquired at an average cost of GBX 950 per share, with a total value of £1,795.50.
Andrew Stephen Thomis also recently made the following trade(s):
- On Tuesday, September 9th, Andrew Stephen Thomis sold 21,203 shares of Cohort stock. The shares were sold at an average price of GBX 1,256, for a total transaction of £266,309.68.
Cohort Stock Up 0.8%
Shares of LON:CHRT opened at GBX 1,290 on Friday. The company has a quick ratio of 0.93, a current ratio of 1.55 and a debt-to-equity ratio of 37.28. Cohort plc has a 52-week low of GBX 860 and a 52-week high of GBX 1,796. The company has a 50 day moving average of GBX 1,313.59 and a two-hundred day moving average of GBX 1,392.42. The company has a market capitalization of £588.63 million, a price-to-earnings ratio of 2,915.25 and a beta of 0.56.
Analyst Ratings Changes
Separately, Shore Capital reaffirmed a “buy” rating and issued a GBX 1,630 price objective on shares of Cohort in a research report on Wednesday, July 16th. One equities research analyst has rated the stock with a Buy rating, According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus target price of GBX 1,630.
Read Our Latest Stock Analysis on CHRT
Cohort Company Profile
Cohort plc is the parent company of seven innovative, agile and responsive businesses based in the UK, Australia, Germany and Portugal, providing a wide range of services and products for domestic and export customers in defence and related markets.
The Group is split into two segments:
Communications and Intelligence
– EID designs and manufactures advanced communications systems for naval and military customers.
Featured Stories
- Five stocks we like better than Cohort
- Expert Stock Trading Psychology Tips
- Salesforce’s Long-Awaited Inflection is Here: Rally On!
- How to Invest in the FAANG Stocks
- Rocket Lab USA Receives Wall Street Validation: Time to Buy?
- What Investors Need to Know About Upcoming IPOs
- Archer Buys Rival’s Patent Treasure Trove in Strategic Move
Receive News & Ratings for Cohort Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cohort and related companies with MarketBeat.com's FREE daily email newsletter.